Phase 4
N=32
Angiotensin II in General Anesthesia
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT03733145 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Median Dose Required to Increase the Systolic Blood Pressure (SBP) — 35; 43; 45 ng/kg/min
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Angiotensin II (Drug)
- Age
- Adult, Older Adult · 40+ yrs
- Sex
- All
- Sponsor
- Wake Forest University Health Sciences
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Median Dose Required to Increase the Systolic Blood Pressure (SBP) |
35; 43; 45 | — |
| SECONDARY Median Serum Level of Bradykinin 1-8 |
127043; 105405; 101169 | — |
| SECONDARY Median Serum Level of Bradykinin 1-7 |
24457; 19335; 17438 | — |
| SECONDARY Median Serum Level of Bradykinin 1-5 |
2341; 353; 375 | — |
| SECONDARY Median Serum Level of Aldosterone |
293; 293; 230 | — |
| SECONDARY Median Serum Level of Angiotensin I |
8.7; 1.8; 0 | — |
| SECONDARY Median Serum Level of Angiotensin II |
10.9; 31.2; 10.2 | — |
| SECONDARY Median Serum Level of Angiotensin IV |
0; 1; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 1-7 |
8.7; 1.8; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 1-5 |
0; 0; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 1-9 |
0; 0; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 2-10 |
0; 0; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 2-7 |
0; 0; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 3-7 |
0; 0; 0 | — |
| SECONDARY Median Serum Level of Angiotensin 1-12 |
940; 1011; 674 | — |
Summary
Hypotension in adult patients undergoing general anesthesia is common. This can lead to hypoperfusion of vital organs, organ damage, and states of increased metabolic duress. This may be worse in patients with underlying essential hypertension and worse in patients taking Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARBs). Intravenous (IV) administration of Ang II may be an effective treatment of hypotension in this patient population.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of hypertension and treatment with at least one medication including an ACE inhibitor, ARB, and other agents for greater than 2 months
- Patients undergoing general anesthesia
Exclusion Criteria
- BMI > 40
- History of deep venous thrombosis / thromboembolic disease
- History of stroke,
- Baseline SBP of ≥ 160 mmHg,
- History of myocardial infarction or cardiac stents
- Difficult airway
- Asthma
- Congestive heart failure
- Chronic obstructive pulmonary disease
- Pregnant patients
Data sourced from ClinicalTrials.gov (NCT03733145). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.